• Jie Gu, Chunlai Lu, Jing Guo, Lingli Chen, Yiwei Chu, Yuan Ji, and Di Ge.
• Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
• J Surg Oncol. 2013 Apr 1; 107 (5): 474-80.

BackgroundA new classification of pulmonary adenocarcinoma has been recently proposed by the International Association for the Study of Lung Cancer, American Thoracic Society and European Respiratory Society (IASLC/ATS/ERS). This study was undertaken in an attempt to explore the clinical implication of this new classification in Chinese patients.MethodsTwo hundred ninety-two lung adenocarcinomas were reclassified strictly according to the IASLC/ATS/ERS classification by two pathologists, independently. Kaplan-Meier and Cox regression analyses were used to analyze the correlation between the new classification and patients' prognosis.ResultsWe confirmed three groups with different outcomes. Both AIS and MIA had 100% 5-year disease-free survival rate and 100% 5-year overall survival rate. Lepidic, acinar, and papillary as well as variants of invasive adenocarcinoma had intermediate prognosis. Solid and micropapillary cases had poor prognosis (DFS: P < 0.001, OS: P = 0.002). After controlling the clinicopathological factors, the new classification was identified as an independent prognostic factor in patients' disease-free survival and overall survival.ConclusionsWe have demonstrated a valuable prognostic role of the new classification in Chinese patients. This new classification is valuable of screening out patients with high risk of recurrence to receive postoperative adjuvant therapy.Copyright © 2012 Wiley Periodicals, Inc.

26 keywords...

hide…